| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/29/2003 | EP1278870A1 Splice variant of camp phosphodiesterase type 7 (pde7a3) |
| 01/29/2003 | EP1278869A2 Proteases |
| 01/29/2003 | EP1278859A2 Human protein kinases and protein kinase-like enzymes |
| 01/29/2003 | EP1278853A2 Listeria monocytogenes genome, polypeptides and uses |
| 01/29/2003 | EP1278846A2 Cytoskeleton-associated proteins |
| 01/29/2003 | EP1278843A2 Rna metabolism proteins |
| 01/29/2003 | EP1278842A2 Dna encoding the prost 03 polypeptide |
| 01/29/2003 | EP1278840A2 Isolated human g-protein coupled receptors of the mas proto-oncogene subfamily, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 01/29/2003 | EP1278839A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 01/29/2003 | EP1278838A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 01/29/2003 | EP1278829A2 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema |
| 01/29/2003 | EP1278827A2 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 01/29/2003 | EP1278826A1 Novel proteins |
| 01/29/2003 | EP1278776A2 Isolated human transporter proteins, nucleic acids and uses thereof |
| 01/29/2003 | EP1278775A2 Isolated human g-protein coupled receptors that are members of the aminergic subfamily, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 01/29/2003 | EP1278774A2 Human g-protein coupled receptors |
| 01/29/2003 | EP1278766A2 Polynucleotides for diagnosing mammary gland cancer |
| 01/29/2003 | EP1278759A1 Bis-(n,n'-bis-(2-haloethyl)amino) phosphoramidates as antitumor agents |
| 01/29/2003 | EP1278749A1 USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS |
| 01/29/2003 | EP1278734A2 Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore |
| 01/29/2003 | EP1278732A1 1-aroyl-piperidinyl benzamidines |
| 01/29/2003 | EP1278716A1 Cyclohexylamine derivative as subtype selective nmda receptor antagonists |
| 01/29/2003 | EP1278574A2 Topical composition for the treatment of psoriasis and related skin disorders |
| 01/29/2003 | EP1278547A2 Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
| 01/29/2003 | EP1278545A1 Combination therapy of respiratory diseases using antibodies |
| 01/29/2003 | EP1278540A2 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis |
| 01/29/2003 | EP1278530A2 Chemical modification of mammalian urine and blood |
| 01/29/2003 | EP1278525A2 Methods and compositions for enhancing cellular function through protection of tissue components |
| 01/29/2003 | EP1278522A2 Pde-v inhibitors for treatment of parkinson's disease |
| 01/29/2003 | EP1278520A1 Diaryl piperidyl pyrrole derivatives as antiprotozoal agents |
| 01/29/2003 | EP1278519A2 Method for treating a patient with neoplasia by treatment with a topoisomerase i inhibitor |
| 01/29/2003 | EP1278518A2 A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer |
| 01/29/2003 | EP1278517A2 Methods for improving size and appearance of a wound |
| 01/29/2003 | EP1182931A4 Stable biocidal compositions |
| 01/29/2003 | EP1119334B1 Two chamber cartridge for atomizers |
| 01/29/2003 | EP1024815B1 Pharmaceutical compositions for oral administration of molecular iodine |
| 01/29/2003 | EP0572560B1 Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
| 01/29/2003 | CN1394140A Prostaglandin compositions and method of treatment for male erectile dysfunction |
| 01/29/2003 | CN1393223A Application of Na-ion channel blocker and aspirin in preparing antalgic medicine for mammal |
| 01/29/2003 | CN1393222A Composition for reparing tissue and regenerating organs by internal in-situ culture and regeneration of stem cells |
| 01/29/2003 | CA2417631A1 Selective pde 2 inhibitors, used as medicaments for improving cognition |
| 01/28/2003 | US6512166 Combinations of fungal cell wall degrading enzyme and fungal cell membrane affecting compound |
| 01/28/2003 | US6512104 Interleukin-1β converting enzyme like cysteine protease |
| 01/28/2003 | US6512072 Formulation for depositing a film on a substrate comprising 5 to79.9 wt. % of an alkylene trialkoxy terminated polysiloxane; 0.01 to 5 wt. % of a catalyst; 20 to 94.99 to wt % of a volatile diluent, and, optionally, 0.01 to 5 wt. % of an |
| 01/28/2003 | US6512023 An adhesive composition includes a polymerizable adhesive monomer, at least one vapor phase stabilizer, and at least one liquid phase stabilizer. The combination of at least one vapor phase stabilizer and at least one liquid phase |
| 01/28/2003 | US6512009 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator |
| 01/28/2003 | US6512004 Promoters of neural regeneration |
| 01/28/2003 | US6512002 Methods of treatment for premature ejaculation in a male |
| 01/28/2003 | US6511986 Method of treating estrogen receptor positive carcinoma |
| 01/28/2003 | US6511983 Pharmaceutical combination of antiviral agents |
| 01/28/2003 | US6511981 Benzyl isooxazole and benzyl pyrazole derivatives as aldose reductase and cyclooxygenase-2 inhibitors |
| 01/28/2003 | US6511980 For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder |
| 01/28/2003 | US6511979 Methods for treating conditions modulated by lactosylceramide |
| 01/28/2003 | US6511973 Enzyme inhibitors of blood coaggulation factor X for use as anticoaggulants in the treatment of cardiovascular diseases associated with thromboses |
| 01/28/2003 | US6511968 COX-2 inhibitor, or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of aspirin; does not contain HMG-CoAreductase inhibitor |
| 01/28/2003 | US6511960 Also cromolyn salts or esters; may be in combination with a corticosteroid; may also contain an antiphlogistic compound and hyaluronic acid |
| 01/28/2003 | US6511825 Cell signaling polypeptides and nucleic acids |
| 01/28/2003 | US6511811 Protein kinase C antagonist related to insulin receptor |
| 01/28/2003 | US6511807 Carbohydrate ligand that specifically binds to a leczyme; nucleic acid sequence encoding a nonclassical MHC class I heavy chain; ability to associate with a beta 2 microglobulin; major histocompatibility complex transplantation molecules |
| 01/28/2003 | US6511676 Forming cisplatin and ethanol buffered solution; combining with a negatively charged phosphatidyl glycerol lipid deriva-tive; able to reach primary tumors and their metastases after intravenous injection; breast and prostate cancer |
| 01/28/2003 | US6511675 Dietary supplements |
| 01/28/2003 | US6511662 Treatment of cytomegalovirus using aminopeptidase N |
| 01/28/2003 | US6511659 Treatment of alopecia, cosmetics |
| 01/28/2003 | CA2307101C Pharmaceutical articles of manufacture comprising selective phosphodiesterase inhibitors for the treatment of sexual dysfunction |
| 01/28/2003 | CA2284910C Pharmaceutical combined preparations containing erythropoietin and iron preparations |
| 01/28/2003 | CA2148839C Use of alpha-1c specific compounds to treat benign prostatic hyperplasia |
| 01/28/2003 | CA2033469C Composition and method for the treatment of osteoporosis in mammals |
| 01/27/2003 | WO2002007713A2 Medicaments containing cilansetron for treating non-obstipated male ibs patients |
| 01/27/2003 | CA2417677A1 Medicaments containing cilansetron for treating non-obstipated male ibs patients |
| 01/27/2003 | CA2391642A1 Identification and use of molecules implicated in pain |
| 01/27/2003 | CA2391219A1 Identification and use of molecules implicated in pain |
| 01/27/2003 | CA2391216A1 Identification and use of molecules implicated in pain |
| 01/27/2003 | CA2391112A1 Identification and use of molecules implicated in pain |
| 01/24/2003 | WO2002008456A2 Method for identifying metastatic tumor cells |
| 01/24/2003 | CA2416697A1 Method for identifying metastasizing tumor cells |
| 01/23/2003 | WO2003006996A2 Natural ligand of gpcr chemr23 and uses thereof |
| 01/23/2003 | WO2003006995A2 Method for identifying substances which modulate interleukin 4 (il-4) signaling |
| 01/23/2003 | WO2003006893A2 Methods of inhibiting amyloid toxicity |
| 01/23/2003 | WO2003006646A1 Regulation of human aminopeptidase n |
| 01/23/2003 | WO2003006611A2 GPCs AS MODIFIERS OF THE IRRTK AND p21 PATHWAYS AND METHODS OF USE |
| 01/23/2003 | WO2003006495A2 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket |
| 01/23/2003 | WO2003006490A1 Bridged bicyclic serine protease inhibitors |
| 01/23/2003 | WO2003006447A2 Interaction inhibitors of tcf-4 with beta-catenin |
| 01/23/2003 | WO2003006434A1 Metal complexes for use in boron neutron capture therapy |
| 01/23/2003 | WO2003006062A1 Pharmaceutical agents containing acyclovir, fusaric acid and derivatives thereof |
| 01/23/2003 | WO2003006059A1 Vegfr-1 antibodies to treat breast cancer |
| 01/23/2003 | WO2003006057A1 Composition and method for the treatment of disease |
| 01/23/2003 | WO2003006045A2 Cxcl10 treatment of secondary tissue degeneration |
| 01/23/2003 | WO2003006044A1 Methods and compositions for controlling protein assembly or aggregation |
| 01/23/2003 | WO2003006042A1 Peptide for regulation of tissue plasminogen activator |
| 01/23/2003 | WO2003006026A1 Combinations for the treatment of inflammatory disorders |
| 01/23/2003 | WO2003006017A2 Use of certain castanospermine esters in the treatment of influenza virus infections |
| 01/23/2003 | WO2003006005A1 Composition comprising sulfacetamide and a sunscreen for the treatment of rosacea |
| 01/23/2003 | WO2003006002A1 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| 01/23/2003 | WO2003006001A1 ß-ADRENERGIC BLOCKADE REVERSAL OF CATABOLISM AFTER SEVERE BURN |
| 01/23/2003 | WO2003005998A2 A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent of modulating cholinergic function |
| 01/23/2003 | WO2003005991A1 A core formulation |
| 01/23/2003 | WO2003005988A1 Cosmetic and dermatological preparations containing creatine for treating and actively preventing dry skin and other negative alterations of the physiological homeostasis of healthy skin |
| 01/23/2003 | WO2003005968A2 Dual release levodopa ethyl ester and decarboxylase inhibitor with immediate release levodopa |
| 01/23/2003 | WO2003005967A2 Dual release levodopa ethyl ester and decarboxylase in controlled release core |